Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2020-11-25 Director's Dealing
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Director Dealing
Director's Dealing Classification · 100% confidence The document is an official announcement released via RNS (RNS Number: 4915G) on November 25, 2020. The primary subject matter, explicitly stated in the title and body, is 'Director Dealing'. The content details a purchase of ordinary shares by a Director, Clifford Holloway, and includes the mandatory disclosure table titled 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES'. This directly corresponds to the definition of Director's Dealing (Code: DIRS). Although it is an RNS filing, the specific nature of the content overrides the general fallback.
2020-11-25 English
Results of Annual General Meeting
AGM Information Classification · 100% confidence The document is an official announcement filed via RNS (Regulatory News Service) on November 17, 2020. The title explicitly states "Results of Annual General Meeting" and the body confirms that "all resolutions proposed at the Annual General Meeting held today were duly passed." This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, or in this case, the official results announcement following the meeting.
2020-11-17 English
Appointment of CMO and Medical Director
Board/Management Information Classification · 98% confidence The document begins with 'RNS Number : 6038F' and is dated '17 November 2020'. It announces the 'Appointment of Dr Gillies O'Bryan-Tear as Chief Medical Officer and Dr Robert Miller as Medical Director'. This is a specific announcement regarding changes in senior management/board personnel. This directly matches the definition for Board/Management Information (MANG). Although it originates from RNS, the content is highly specific to management changes, making MANG the most accurate classification over the general RNS fallback.
2020-11-17 English
Director Dealing
Director's Dealing Classification · 100% confidence The document is clearly identified by the 'RNS Number' header and contains the title 'Director Dealing'. The content details the purchase of ordinary shares by 'Vulpes Life Sciences Fund', which is a 'person closely associated with Martin Diggle, Non-Executive Director'. This directly matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The corresponding code is DIRS.
2020-11-13 English
Director Dealing
Director's Dealing Classification · 100% confidence The document is an official announcement released via RNS (RNS Number : 8802E) on November 10, 2020. The title and content explicitly state 'Director Dealing' and detail a subscription for ordinary shares by a person closely associated with a Non-Executive Director (Vulpes Life Sciences Fund associated with Martin Diggle). This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). The specific section header 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM' confirms this classification. Therefore, the appropriate code is DIRS.
2020-11-10 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document text is very short (1939 characters) and contains the header 'RNS Number : 7126E' and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Second Price Monitoring Extension' for a security, which is a specific, immediate operational announcement related to trading status, not a comprehensive financial report or a standard regulatory filing like 10-K or IR. Since it is a general regulatory announcement provided via the RNS service that doesn't fit into the more specific categories (like DIV, DIRS, ER, etc.), the most appropriate classification is the general regulatory announcement fallback category, RNS.
2020-11-09 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.